Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
Portfolio Pulse from Benzinga Insights
Editas Medicine (NASDAQ:EDIT) has received mixed analyst ratings over the past three months, with a decrease in average price target from $16.17 to $10.86. Analysts have adjusted their ratings and price targets, reflecting changing sentiments. The company faces financial challenges, including a significant revenue decline and negative net margin, but maintains a strong market presence with a high market capitalization.
October 23, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Editas Medicine has received a range of analyst ratings, with a notable decrease in the average price target from $16.17 to $10.86. Analysts have adjusted their ratings, reflecting a cautious outlook amid financial challenges such as declining revenue and negative net margin.
The decrease in the average price target and mixed analyst ratings suggest a cautious outlook for Editas Medicine. The company's financial challenges, including a significant revenue decline and negative net margin, contribute to the negative sentiment. These factors are likely to impact the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100